ArticleCancer research communications2026
Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hepatic stellate cells (HSCs) and their derived cancer-associated fibroblasts (CAFs) are integral to the development, progression, and prognosis of hepatocellular carcinoma (HCC). However, the mechanisms underlying the transformation of HSCs into CAFs and their subsequent roles in HCC remain incompletely understood. The expression of METTL3 was analyzed in fibroblasts infiltrating into human HCC specimens compared with adjacent nontumor tissues. The effects of HSC-specific METTL3 deficiency on HCC were analyzed by orthotopically implanting hepatoma cells into the fibrotic mouse livers, as well as through direct and indirect co-culture systems. We found that the expression of METTL3, the methyltransferase responsible for RNA N6-methyladenosine (m6A) modification, was downregulated in fibroblasts infiltrating into HCC compared with that of adjacent nontumor tissues. Orthotopical implantation of HCC cells in the fibrotic liver showed that HSC-specific METTL3 deficiency significantly increased tumor burden. Furthermore, conditioned medium treatment and mixed coculture confirmed that METTL3 deletion in HSCs promoted HCC proliferation and migration in vitro, demonstrating that METTL3 deficiency in HSCs accelerated HCC progression in the fibrotic liver. Mechanistically, METTL3 deficiency reduced m6A modification and expression of bone morphogenetic protein 10 (BMP10), a known tumor suppressor. Similar to the effects of METTL3 deficiency, BMP10 knockdown also promoted hepatoma cell growth, whereas recombinant BMP10 (rBMP10) inhibited it. Notably, BMP10 overexpression or rBMP10 supplementation effectively mitigated the tumor-promoting effects of METTL3-deficient HSCs. BMP10's effects were mediated through SMAD1/5/8 phosphorylation. Collectively, our study reveals a novel crosstalk between HSCs and hepatoma cells via the METTL3/m6A-BMP10-SMAD1/5/8 axis, highlighting a potential therapeutic target for HCC. SIGNIFICANCE: In this study, we found that HSC-specific METTL3 deficiency significantly accelerated HCC progression in the fibrotic liver. Mechanistically, METTL3 deficiency reduced m6A modification and expression of BMP10 and the downstream SMAD1/5/8 phosphorylation. This study reveals a novel crosstalk between HSCs and hepatoma cells, suggesting a potential therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.